Emerging Research Highlights Unexpected Risks of GLP-1 Medications
WHO:
Gizmodo - Researchers from the University of Pennsylvania conducted the study.
ScienceAlert - The study was led by a team from the University of Pennsylvania.
WHAT:
Gizmodo - The study published in The BMJ indicates that approximately 200 out of 12,000 GLP-1 users developed alopecia during the study period, which is roughly 1.6%.
Euronews.com - The study confirms that the most observed cases of hair loss linked to GLP-1 were reversible, as hair follicles remained intact.
NY Post - New studies suggest a higher risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes.
Gizmodo - GLP-1 medications like semaglutide and tirzepatide may lead to hair loss, with a 37% higher likelihood of alopecia compared to SGLT-2 inhibitors and a 68% higher likelihood compared to DPP-4 inhibitors.
ScienceAlert - The study found a notable link between GLP-1 treatments and hair thinning, specifically non-scarring alopecia.
WHERE:
Gizmodo - The study analyzed data from patients receiving care within the University of Pennsylvania Health System, or Penn Medicine.
WHEN:
Gizmodo - The study analyzed data from roughly 12,000 people with type 2 diabetes who were newly prescribed a GLP-1 between 2019 and 2024.
ScienceAlert - The study involved 12,004 patients using GLP-1 drugs compared to 15,221 using SGLT-2 inhibitors and an additional 11,964 GLP-1 users compared to 11,233 using DPP-4 inhibitors.
WHY:
Euronews.com - The authors noted that rapid weight loss and reduced calorie intake are well-established triggers of hair shedding, and hormonal changes may also play a role.
Gizmodo - The researchers suggest that rapid or substantial weight loss associated with GLP-1 use may trigger a type of temporary hair loss called telogen effluvium.
ScienceAlert - Weight loss and changes in nutritional status, common consequences of GLP-1 receptor agonist therapy, are established risk factors for telogen effluvium.
HOW:
ScienceAlert - The study involved a large number of people: 12,004 patients using GLP-1 drugs were compared to 15,221 using SGLT-2 inhibitors, with an additional 11,964 GLP-1 users compared to 11,233 using DPP-4 inhibitors.
Gizmodo - The study compared GLP-1 users to similarly sized groups of patients taking SGLT-2 inhibitors or DPP-4 inhibitors, adjusting for factors like age and sex.
ScienceAlert - The researchers factored in other variables that could account for hair loss risk, including age, sex, ethnicity, and pre-existing conditions.
(UPDATED July 24, 2026 01:27 UTC)
A recent study published in The BMJ found that about 200 out of 12,000 users of GLP-1 medications experienced alopecia, which translates to roughly 1.6% of participants, and most cases of hair loss were reversible. The authors pointed out that rapid weight loss and reduced calorie intake are known triggers for hair shedding, with hormonal changes potentially contributing as well. The research involved a substantial sample size, comparing 12,004 GLP-1 users to 15,221 using SGLT-2 inhibitors, and an additional 11,964 GLP-1 users against 11,233 using DPP-4 inhibitors.
--
(UPDATED July 23, 2026 16:25 UTC)
Researchers from the University of Pennsylvania have found that patients taking GLP-1 medications for obesity or diabetes, such as semaglutide and tirzepatide, face a significantly higher risk of hair loss, with a 37% increased likelihood of alopecia compared to those using SGLT-2 inhibitors. The study, which analyzed data from over 12,000 patients newly prescribed GLP-1 drugs between 2019 and 2024, suggests that rapid weight loss associated with these treatments may trigger a temporary type of hair loss known as telogen effluvium. The researchers adjusted their findings for various factors, including age, sex, and pre-existing conditions, to draw these conclusions.